Review of the Chest CT Differential Diagnosis of Ground-Glass Opacities in the COVID Era | Radiology
pulmonary hypertension and left heart failure :: Article Creator Tectonic Bets On GPCR Heart Failure Drug Following Reverse Merger With Avrobio Tectonic Therapeutic has completed a reverse merger with Avrobio and will begin trading on the Nasdaq global market as Tectonic Therapeutic (ticker symbol 'TECX') on 21 June. Coinciding with the merger, the new company also completed a private placement of $130.7m with multiple US and European investors. Following the placement, Tectonic reported total cash reserves of $181m, before payment of final transaction-related expenses, which is expected to fund operations until mid-2027. As part of the merger, Avrobio enacted a 1-for-12 reverse stock split of its common shares, along with an issuance of a non-transferable contingent value right. Under that, shareholders will have the rights to cash payments received by Tectonic, if any, related to Avrobio's pre-transaction legacy assets. Avrobio...